What is the main takeaway for pharma teams?

The ODAC meeting provided critical insights on camizestrant's efficacy and safety, highlighting the importance of addressing unmet medical needs in oncology.

Who published this and why does it matter?

Published by the FDA/CDER, this document is crucial for understanding regulatory perspectives and the advisory committee's recommendations on camizestrant.

What should BD or regulatory teams do next?

Teams should monitor the outcomes of the advisory committee's discussions and prepare for potential regulatory changes based on the meeting's findings.

Whitepaper US Score 89/100

FDA's April 30, 2026 ODAC Meeting on Camizestrant Review

Insights from the April 30, 2026 ODAC meeting regarding camizestrant's efficacy and safety.

Publisher: FDA/CDER
Length: 99 pages
File: 0 B PDF

Download Whitepaper

High impact FDA/CDER 198 min read

Why this matters

Camizestrant is under review for the treatment of ESR1m/HR+/HER2- advanced breast cancer (ABC).

Executive summary

Camizestrant is under review for the treatment of ESR1m/HR+/HER2- advanced breast cancer (ABC).
The ODAC meeting will focus on evaluating camizestrant's clinical efficacy and safety profile, based on data from studies like SERENA-6.
The FDA emphasizes addressing the unmet medical need in patients with ESR1m/HR+/HER2- ABC. The agency seeks the committee's insights and opinions to inform regulatory decisions.
A fully accessible version of the meeting materials will be posted for individuals using assistive technology.
The FDA encourages public input regarding any accessibility barriers encountered with the meeting materials.

AI research brief

Insights from the April 30, 2026 ODAC meeting regarding camizestrant's efficacy and safety.

Market Impact

Regulatory	high
Commercial	high
Competitive	medium
Investment	high

Who should read this

Regulatory affairs teams

Ask about this report

AI-assisted answers grounded in NovaPharmaNews intelligence

Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.

⬇

Download the full 99-page PDF

Free · 0 B · Instant access after email

This document outlines the agenda and briefing materials for the FDA's Oncologic Drugs Advisory Committee (ODAC) meeting on April 30, 2026, concerning the review of camizestrant.

Key Takeaways

Camizestrant is under review for the treatment of ESR1m/HR+/HER2- advanced breast cancer (ABC).
The ODAC meeting will focus on evaluating camizestrant's clinical efficacy and safety profile, based on data from studies like SERENA-6.
The FDA emphasizes addressing the unmet medical need in patients with ESR1m/HR+/HER2- ABC. The agency seeks the committee's insights and opinions to inform regulatory decisions.
A fully accessible version of the meeting materials will be posted for individuals using assistive technology.
The FDA encourages public input regarding any accessibility barriers encountered with the meeting materials.

What is the purpose of the ODAC meeting?

The meeting aims to gather the advisory committee’s insights and opinions on camizestrant, focusing on issues identified by the FDA for discussion. The FDA will consider the input from the advisory committee process and all reviews before making a final determination.

Why is this ODAC meeting important for pharma teams?

Understanding the discussions and outcomes of this meeting is essential for pharmaceutical teams to navigate regulatory pathways and align their strategies with FDA expectations regarding the treatment of ESR1m/HR+/HER2- ABC.

Frequently Asked Questions

What is the proposed indication for camizestrant?

Camizestrant is being reviewed for treating patients with ESR1m/HR+/HER2- advanced breast cancer.

What efficacy data will be discussed at the meeting?

The SERENA-6 study design, patient selection, efficacy endpoints, and statistical methodology will be discussed, along with an overview of efficacy results.

What safety information will be reviewed?

The meeting will cover the extent of exposure, overview of adverse events, adverse events with an outcome of death, identified adverse drug reactions, and other safety topics of interest related to camizestrant.

Related coverage

Ready to read the full report?

Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.

Download PDF ↓